Intercept Unlikely To Refile OCA For NASH Before Late 2021

 
• By Joseph Haas

Once determined to resubmit its NDA by the end of 2020, Intercept now says talks with the FDA have presented a new path to approval in non-alcoholic steatohepatitis that could mean refiling sometime in 2021.

Binocular viewer_1200X675
Intercept can see a path forward in NASH, but it will take a while

More from New Products

More from Scrip